Common Contracts
5 similar Tender and Support Agreement contracts by Amgen Inc, Anadys Pharmaceuticals Inc, Hyperion Therapeutics Inc, others
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • March 30th, 2015 • Hyperion Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of March 29, 2015, by and among Horizon Pharma, Inc., a Delaware corporation (“Parent”), Ghrian Acquisition Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”), and (“Stockholder”).
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • September 23rd, 2013 • Verenium Corp • Industrial organic chemicals • Delaware
THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of September 19, 2013, by and among BASF CORPORATION, a Delaware corporation (“Parent”), PASTINACA ACQUISITION INC., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”) and [ ] (“Stockholder”).
FORM OF TENDER AND SUPPORT AGREEMENTTender and Support Agreement • January 27th, 2012 • Micromet, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of January 25, 2012, by and among Amgen Inc., a Delaware corporation (“Parent”), Armstrong Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”), and (“Stockholder”).
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • January 26th, 2012 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of January 25, 2012, by and among Amgen Inc., a Delaware corporation (“Parent”), Armstrong Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”), and (“Stockholder”).
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • October 19th, 2011 • Anadys Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of October 16, 2011, by and among Hoffmann-La Roche Inc., a New Jersey corporation (“Parent”), Bryce Acquisition Corporation, a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”), and [ ] (the “Stockholder”).
